{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-015887","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.757352+00:00","generated_at":"2026-05-16T02:26:48.891796+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics Q1 FY2026 net loss $23.1M; unit sales of LYTENAVA double in Europe","bullets":["Net loss of $23.1M ($0.38/share) vs net income of $17.4M ($0.72/share) in prior-year quarter.","Adjusted net loss $13.5M ($0.22/share) vs adjusted net loss $21.6M ($0.89/share) a year ago.","Revenue negatively impacted by returns reserve for short-dated product from UK distributor; unit sales more than doubled QoQ.","Cash and equivalents $8.7M as of Dec 31, 2025 (excluding $2.4M ATM proceeds post-quarter).","Submitted Type A meeting request to FDA to discuss ONS-5010 CRL for wet AMD; additional EU launches planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-015887","json":"https://secwatch.observer/filing/0001104659-26-015887.json","markdown":"https://secwatch.observer/filing/0001104659-26-015887.md","text":"https://secwatch.observer/filing/0001104659-26-015887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/0001104659-26-015887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:26:48.891796+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}